Rugo, Hope S. http://orcid.org/0000-0001-6710-4814
Pennella, Eduardo J.
Gopalakrishnan, Unmesh
Hernandez-Bronchud, Miguel
Herson, Jay
Koch, Hans Friedrich
Loganathan, Subramanian
Deodhar, Sarika
Marwah, Ashwani
Manikhas, Alexey
Bondarenko, Igor
Mukhametshina, Guzel
Nemsadze, Gia
Parra, Joseph D.
Abesamis-Tiambeng, Maria Luisa T.
Baramidze, Kakhaber
Akewanlop, Charuwan
Vynnychenko, Ihor
Sriuranpong, Virote
Mamillapalli, Gopichand
Roy, Sirshendu
Yanez Ruiz, Eduardo Patricio
Barve, Abhijit
Fuentes-Alburo, Adolfo
Waller, Cornelius F.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
https://doi.org/10.1007/s10549-021-06197-5
Funding for this research was provided by:
Viatris Inc
Article History
Received: 11 January 2021
Accepted: 16 March 2021
First Online: 14 June 2021
Declarations
:
: HS Rugo has received travel, accommodations, and expenses from Amgen, Merck, Viatris Inc, Pfizer, and Puma Biotechnology and research funding (provided to the Regents of the University of California) from Eisai, Genentech/Roche, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Daiichi, Immunomedics, and Pfizer. EJ Pennella was a paid employee of Mylan Inc (now Viatris Inc) during the time of the study and may hold stock with the company. U Gopalakrishnan, K Beckmann, HF Koch, A Barve, and A Fuentes-Alburo are paid employees of Viatris Inc and may hold stock with the company. M Hernandez-Bronchud has served as a consultant/advisory board member for Viatris Inc. S Loganathan, S Deodhar, and A Marwah are paid employees of Biocon Research Ltd and may hold stock with the company. C Akewanlop has received travel, accommodations, and expenses from Amgen, AstraZeneca, Roche, and Bristol-Myers Squibb. CF Waller is a consultant/advisory board member for Viatris Inc. J Herson, A Manikhas, I Bondarenko, G Mukhametshina, G Nemsadze, JD Parra, MLT Abesamis-Tiambeng, K Baramidze, I Vynnychenko, V Sriuranpong, G Mamillapalli, S Roy, and EP Yanez Ruiz have nothing to disclose.
: This study was conducted in accordance with the International Council for Harmonisation Guidance for Industry E6 Good Clinical Practice, the Declaration of Helsinki, and applicable local regulatory requirements. All patients provided written informed consent before starting any study-related procedures. The full trial protocol and all other relevant study documentation were approved by the institutional review board or ethics committee at each study center before study initiation.
: All patients provided written informed consent before starting any study-related procedures.